Please login to the form below

Not currently logged in

GSK driving growth in emerging markets

GlaxoSmithKline has entered into a transformational agreement with South African pharmaceutical company
GlaxoSmithKline (GSK) has entered into a transformational agreement with South African pharmaceutical company, Aspen, as a part of a new strategy to accelerate sales growth in emerging markets and extend its product portfolio.

Under the terms of the agreement with Aspen and its venture partner, Strides Arcolab, GSK will access to a broad portfolio and future pipeline of branded pharmaceutical products on a licence and supply basis across emerging markets.

According to GSK, emerging markets are predicted to grow by 13 per cent - triple the growth rates of Western markets - and will account for 40 per cent of the worldwide pharmaceutical market by 2020. In an attempt to tap into this potential resource, GSK has established a new business model and prioritised investments to boost its geographical footprint in emerging market countries.

"This collaboration gives us access to a renewable, high quality and competitively priced source of branded pharmaceuticals in high demand therapeutic areas," said Andrew Witty, CEO of GSK. "Growth in both population and economic prosperity is leading to increased demand for branded pharmaceutical products."

23rd July 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...